StageZero Life Sciences Partners With My One Medical Source and 1,000+ Medical Access Points in the USA
StageZero Life Sciences Partners With My One Medical Source and 1,000+ Medical Access Points in the USA
Aristotle and AVRT to be offered to My One Medical Source's Customer Base
亞里士多德和 AVRT 將提供給 My One Medical Source 的客戶群
TORONTO, ON / ACCESSWIRE / November 14, 2023 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announces it is partnering with My One Medical Source ("MOMS") to offer the StageZero suite of diagnostics and treatment protocols to MOMS' national customer base.
安大略省多倫多/ACCESSWIRE /2023 年 11 月 14 日/ StageZero 生命科學有限公司（多倫多證券交易所股票代碼：SZLS）（場外交易代碼：SZLSF）(”StageZero“或者”公司“）是一家綜合性醫療保健公司，擁有第一個、也是唯一一個用於從單一血液樣本中篩查多種關鍵癌症的mRNA多癌症診斷——亞里士多德，以及由腫瘤學家主導的帶有早期數據的輔助治療方案——METRICS研究——顯示癌症患者的預後有所改善，該公司宣佈將與My One Medical Source合作（”媽媽們“）向MOMS的全國客戶群提供StageZero診斷和治療方案套件。
"MOMS has over 1,000 Medical Access Points ("MAPS") across the USA and connects providers, employers and patients with clinical laboratories. It instantly establishes a national patient service center network for StageZero and CareOncology and takes our high complexity lab and makes it into 50 State local labs with all of the attendant customer base. MOMS will actively promote StageZero's diagnostic programs" said James Howard-Tripp, Chairman and CEO of StageZero. "Coupled with the CareOncology clinical group providing clinical oversight, and via telehealth, we can cater to all 50 States and actively engage with the MAPS and their customer base, as well as draw in new patients. The new programs we are introducing continue to enhance our visibility" he further added.
“媽媽有 1,000 多個醫療接入點（”地圖“）遍及美國，將提供商、僱主和患者與臨床實驗室聯繫起來。它立即爲StageZero和CareOncology建立了全國患者服務中心網絡，並將我們的高複雜性實驗室帶入了50個州地方實驗室，並擁有所有相關客戶群。媽媽們將積極推廣StageZero的診斷計劃。” StageZero董事長兼首席執行官詹姆斯·霍華德-特里普說。“再加上提供臨床監督的CareOncology臨床小組以及通過遠程醫療，我們可以爲所有50個州提供服務，積極與MAPS及其客戶群互動，並吸引新患者。他進一步補充說：“我們推出的新計劃繼續提高我們的知名度。”
Approximately 1.9 million Americans will be diagnosed with cancer this year, with more than half of them diagnosed with late stage cancer1. Five-year survival rates for stage 3 and 4 cancer is significantly poorer than if it is diagnosed at stage 1 or 2 (eg Colorectal: 90% if found early vs 14% if found late); cost of treating late stage cancer is also 2-4 times higher than treating early stage cancer. It is critical that cancer be diagnosed as early as possible.
今年將有大約190萬美國人被診斷出患有癌症，其中一半以上被診斷出患有晚期癌症1。3期和4期癌症的五年存活率明顯低於診斷爲1或2期的癌症（例如，結直腸癌：如果發現及早，則爲90％，而如果發現晚期，則爲14％）；晚期癌症的治療成本也比治療早期癌症高2-4倍。儘早診斷出癌症至關重要。
The US cancer screening market is $77.4 billion, with a CAGR of 7%2. The economic burden associated with cancer is $150.8 billion3. Self-funded healthcare employers account for approx. 64% of all employers and employ 100 million Americans. Cancer is a key driver of their healthcare costs.4,5,6
美國癌症篩查市場爲774億美元，複合年增長率爲7％2。與癌症相關的經濟負擔爲1,508億美元3。自籌資金的醫療保健僱主約佔所有僱主的64％，僱用了1億美國人。癌症是他們醫療費用的關鍵驅動力。4,5,6
Sources:
來源：
1. American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022. (Accessed 1.30.22); Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
2.
3. National Cancer Institute. Financial burden of cancer care. March 2020. Accessed October 14, 2020. progressreport.cancer.gov/after/economic_burden
4. Kaiser Family Foundation. Health Insurance Coverage of the Total Population [Internet]. KFF (Kaiser Family Foundation). 2022. Available from:
5.
6.
1。美國癌症協會。2022 年癌症事實與數據。亞特蘭大：美國癌症協會；2022 年。（已訪問 1.30.22）；Siegel RL、Miller KD、Fuchs HE、Jemal A. Cancer Statistics，2021 年。CA Cancer J Clin。2021 年 1 月；71 (1): 7-33。
2。
3。國家癌症研究所。癌症治療的經濟負擔。2020 年 3 月。2020 年 10 月 14 日訪問。progressreport.cancer.gov/after/economic_burden
4。凱撒家庭基金會。總人口的健康保險覆蓋範圍 [互聯網]。KFF（凱撒家庭基金會）。2022 年。可從以下地址獲得：
5。
6。
About My One Medical Source:
關於 My One Medical 來源：
My One Medical Source (MOMS) is the go-to resource for all of your testing related needs. They are shifting the existing paradigm of specialized testing for those who need it and those who supply it to a new model that empowers both parties and makes healthcare more accessible.
My One Medical Source (MOMS) 是滿足您所有與測試相關的需求的首選資源。他們正在將爲有需要的人和提供者提供專業檢測的現有模式轉變爲一種新的模式，這種模式既能增強雙方的能力，又使醫療保健更容易獲得。
By building a national network of medical access points, the MOMS platform connects those who need testing with urgent care centers, pharmacies, and private test sites for sample collection.
通過建立全國性的醫療接入點網絡，MOMS平台將需要檢測的人與緊急護理中心、藥房和私人測試場所聯繫起來，以進行樣本採集。
With the more than 13 billion tests performed in over 250,000 labs each year there comes a critical need for an organized, simplified process. The future of test management is here.
每年在超過25萬個實驗室中進行超過130億次測試，因此迫切需要一個有組織、簡化的流程。測試管理的未來就在這裏。
About StageZero Life Sciences, Ltd.
關於 StageZero 生命科學有限公司
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT).
StageZero Life Sciences, Ltd. 是一家垂直整合的醫療保健公司，致力於通過下一代診斷和獨特的遠程醫療計劃改善癌症和其他慢性病的早期發現和管理，這些計劃提供臨床干預措施，以幫助目前患有癌症的患者（COC 協議），並幫助患者降低患晚期疾病（AVRT）的風險。
The Company's next generation test, Aristotle, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Sentinel Principle has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
該公司的下一代測試名爲亞里士多德，是有史以來第一款從單一血液樣本中同時篩查多種癌症的mRNA多癌試劑盒，對每種癌症具有很高的靈敏度和特異性。亞里士多德使用mRNA技術來識別多種癌症類型的分子特徵，並建立在該公司的專利技術平台Sentinel Principle之上。Sentinel 原理已在 9,000 多名患者中得到驗證，北美有 100,000 多名患者使用。
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
Care OncologyClinic爲被診斷患有任何類型或階段的癌症的人提供監督治療方案（COC協議）。COC協議由科學家和腫瘤學家制定，旨在與標準治療癌症療法一起用於輔助給藥。這是一種個性化的治療方法，旨在同時靶向多種代謝性癌症途徑。目的是限制癌細胞的能量供應和使用，這可能會使癌細胞總體上更難存活、生長和適應體內不斷變化的條件。因此，此類細胞可能更容易受到放射療法和化療等殺滅細胞療法的攻擊。其獲得專利的COC協議採用了多方面的方法，得到了同行評審的科學研究的支持，這些研究突顯了某些治療方法有可能針對癌細胞的特定能量需求，影響其生長和繁殖的能力。
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
AVRT 是一項由醫生主導的遠程醫療計劃，用於識別和管理癌症和慢性病的早期預警信號。我們的計劃包括：全面的在線健康評估；測量炎症和新陳代謝標誌物的血液檢查；深入的初步醫生諮詢；定期的醫生隨訪和間隔篩查。
Aristotle, as well as additional cancer diagnostics are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia.
亞里士多德以及其他癌症診斷由公司的臨床實驗室StageZero Life Sciences, Inc. 進行處理，該實驗室是弗吉尼亞州里士滿的CAP認證和CLIA認證的高複雜度參考實驗室。
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
StageZero Life Sciences在多倫多證券交易所上市，股票代碼爲SZLS，在OTCQB上市，代碼爲SZLSF。
Forward-Looking Statements
前瞻性陳述
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
本新聞稿包含以 “期望”、“將” 等詞語和類似表達方式表示的前瞻性陳述，這些陳述反映了公司當前對未來事件的預期。前瞻性陳述涉及風險和不確定性，可能導致公司的實際事件與本文預測的事件存在重大差異。投資者應查閱公司正在進行的季度申報和年度報告，以獲取有關這些前瞻性陳述的風險和不確定性的更多信息。提醒讀者不要依賴這些前瞻性陳述。除非法律要求，否則公司不承擔任何更新這些前瞻性陳述的義務。
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
欲了解更多信息，請聯繫：
投資者關係
麗貝卡·格列柯
1-855-420-7140 分機 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences Ltd
來源： StageZero 生命科學有限公司
譯文內容由第三人軟體翻譯。